ReviewHeliyon2024

Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives.

Francesco Schettini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.